Open Access7 th I nternational I mmunoglobulin C onference: Poster Presentations
Author(s) -
Warnatz K.,
Ballow M.,
Stangel M.,
Bril V.
Publication year - 2014
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.12545
Subject(s) - medicine , chronic inflammatory demyelinating polyneuropathy , immunology , adverse effect , multifocal motor neuropathy , antibody , dosing , transplantation , mismatch negativity , electroencephalography , psychiatry
Summary Immunoglobulin ( I g) therapy is the mainstay of treatment for primary antibody deficiency disorders and has proved to be efficacious in specific autoimmune and inflammatory diseases. Additionally, due to the role of I g in complement activation, it is being used increasingly in solid organ transplantation. Furthermore, I g is the primary or secondary treatment in some immune‐mediated neuropathies such as chronic inflammatory demyelinating polyneuropathy ( CIDP ) or multifocal motor neuropathy ( MMN ). This session discusses trends of I g use in E urope, proposed mechanisms of action, adverse effects and the potential role of I g therapy in transplantation. D r Š edivá reported that I g therapy is available in all E uropean countries, although dosing is not always optimal, due partly to reimbursement plans. Subcutaneous immunoglobulin ( SCIg ) has become increasingly accessible in recent years; however, the chosen route of administration still varies widely between countries. D r B erger's presentation on optimization of I g therapy in neuropathies, and D r R ojavin's report on a pharmacometric model to determine the serum IgG levels achieved by different dosing regimens in primary antibody deficiency ( PAD) patients, led to the challenging concept of using individualized dosing strategies. D r K lehmet reported on the potential benefit of using antigen‐specific T cell responses as a biomarker of IVIg responsiveness in CIDP patients, while D r von G unten provided an insight into the mechanisms of action of I g preparations, suggesting that the immunoregulatory effects of IgG may be mediated by IgG antibodies against glycans. D r B asta reported on the potential thrombogenic adverse effects associated with I g therapy. Although these adverse events are rare, further studies are needed to clarify the relationship between I g replacement and immunomodulatory therapy and these adverse reactions. In transplantation, D r C arbone described that prophylactic IVIg treatment was found to decrease the incidence of severe infection in IgG hypogammaglobulinaemia patients undergoing heart transplantations. Furthermore, D r C latworthy reported that inactivating polymorphisms in the inhibitory receptor FcγRIIB do not impact upon kidney allograft survival.